AASLD – The Liver Meeting 2019 The Liver Meeting bulletinRead our Liver Meeting news bulletin. Experimental treatments for NASH/NAFLDEmricasan and selonsertib fail to improve fibrosis in people with NASH. New & experimental HBV treatmentsTherapeutic hepatitis B vaccine may lead to functional cure. infohep news Hepatocellular carcinoma (HCC) A healthy lifestyle could prevent most liver cancer and liver-related deaths Liz Highleyman / 17 December 2019 A healthy lifestyle, including smoking cessation, moderate drinking, a balanced diet, exercise and weight loss could dramatically reduce the growing burden of liver cancer and deaths due to liver disease, according to a study ... Hepatitis delta Combination therapies show promise against hepatitis D Liz Highleyman / 16 December 2019 Combination regimens using lonafarnib or bulevirtide reduced levels of hepatitis delta virus (HDV) in a majority of people with HDV and hepatitis B virus (HBV) co-infection, researchers reported at the AASLD Liver Meeting ... NAFLD Global burden of deaths and liver cancer due to non-alcoholic fatty liver disease growing Keith Alcorn / 11 December 2019 Non-alcoholic fatty liver disease is a growing cause of liver cancer and death in some regions of the world, an analysis of global reporting on liver disease shows. The findings ... Hepatocellular carcinoma (HCC) Immunotherapy combination improves liver cancer survival Liz Highleyman / 27 November 2019 A combination of nivolumab (Opdivo) and ipilimumab (Yervoy), two different types of checkpoint inhibitor immunotherapy, led to higher response rates and longer survival than nivolumab alone in people with advanced liver cancer, according to a ... Experimental treatments for NASH/NAFLD New NASH therapies show promise in mid-stage studies Liz Highleyman / 26 November 2019 Phase II study results presented at the AASLD Liver Meeting this month in Boston show that a number of experimental therapies improve markers of liver health in people with non-alcoholic steatohepatitis (NASH). ... NAFLD People with fatty liver disease struggle to lose weight Liz Highleyman / 25 November 2019 Losing weight may be especially difficult for people with fatty liver disease due to differences in their metabolism. But nonetheless, some can succeed and doing so improves liver health, according to studies ... Hepatocellular carcinoma (HCC) Sustained response to HCV antivirals boosts liver cancer survival Liz Highleyman / 19 November 2019 People with liver cancer who achieved a sustained virological response (SVR) to direct-acting antiviral (DAA) therapy for hepatitis C saw a reduction in both liver-related and all-cause mortality over five years, according to ... Hepatocellular carcinoma (HCC) Hepatitis B antiviral drugs reduce liver cancer risk Liz Highleyman / 19 November 2019 Treating hepatitis B virus (HBV) with nucleoside/nucleotide antiviral drugs was associated with a lower risk of developing hepatocellular carcinoma (HCC), the most common type of liver cancer, according to studies presented last week ... Sexual transmission Hepatitis C incidence is low among Canadian men on PrEP Liz Highleyman / 18 November 2019 New cases of hepatitis C virus (HCV) infection among Canadian gay and bisexual men taking pre-exposure prophylaxis (PrEP) were uncommon compared with rates previously reported in Europe, according to research ... Transplants from donors with HCV Pre- and post-transplant antiviral treatment prevents hepatitis C transmission in all organ recipients, Canadian study finds Keith Alcorn / 14 November 2019 Adding a cholesterol-lowering drug to direct-acting antivirals (DAAs) prevented hepatitis C infection in all recipients of organ transplants from donors with hepatitis C, Jordan Feld, Research Director of the Toronto Centre for ... View more > Editors' picks from other sources Hepatitis C elimination The U.S. needs extra action to eliminate viral hepatitis, the nation’s deadliest infectious disease STAT / 11 December 2019 Models of care ‘Building bridges’ between PCPs, liver specialists for HCV led to 100% cure Healio / 11 December 2019 View more > Other pages in this section Latest news All the news Conference news Email bulletin archive